Wolfe Research last night downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform without a price target The safety issue for nexiguran ziclumeran hinders the bull thesis, the analyst tells investors in a research note. The firm expects the stock “to become fragile as investors will likely be intolerant of the FDA hold.” Wolfe now sees no fundamental reason to drive the stock higher.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
- FDA appoints Richard Pazdur as Director of CDER
- Intellia Therapeutics downgraded to Hold from Buy at JonesResearch
- Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Intellia Reports Favorable Phase 1 Data for Nex-Z